Compare Natera Inc. Common Stock (NTRA) vs NXP Semiconductors N.V. Common Stock (NXPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs NXP Semiconductors N.V. Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while NXP Semiconductors N.V. Common Stock trades at $218.68 (market cap $57.07B). The key difference: Natera Inc. Common Stock and NXP Semiconductors N.V. Common Stock are close in size by market cap, and NXP Semiconductors N.V. Common Stock pays a 1.79% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and NXP Semiconductors N.V. Common Stock for 5 Days on average.
| NTRA | NXPI | |
|---|---|---|
Market Cap | $57.03B | $57.07B |
Volume | 1,131,157 | 3,033,835 |
Sector | Health | Technology |
52-Week High | $425.64 | $332.67 |
52-Week Low | $179.42 | $184.19 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $56.18B | $65.18B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
NXP Semiconductors (NXPI) trades at $226.32, up 0.49% with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $12.27B in 2025 with a robust 22.56% net margin, while analysts maintain a 65% buy rating with a $282.88 consensus target. Recent news highlights executive stock sales and focus on physical AI leadership.
NXPI offers growth potential driven by earnings beats and strategic positioning in semiconductors, but faces near-term technical pressure and competitive risks. The stock trades below analyst targets, suggesting upside if fundamentals hold. Key risks include market volatility and execution challenges in a cyclical industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About NXP Semiconductors N.V. Common Stock
NXP Semiconductors designs semiconductor solutions for embedded applications. Its products serve automotive, industrial and IoT, mobile, and communications-infrastructure markets.
Read more on NXPI →
